Investing.com â€“ Denmark stocks were lower after the close on Wednesday, as losses in the Chemicals, Healthcare and Financials sectors led shares lower. At the close in Copenhagen, the OMX Copenhagen 20 declined 1.74% to hit a new 52-week low. The best performers of the session on the OMX Copenhagen 20 were Oersted AS (CSE:ORSTED), which rose 3.04% or 9.10 points to trade at 308.70 at the close. Meanwhile,  Vestas Wind  Systems A/S (CSE:VWS) added 0.25% or 0.20 points to end at 95.80 and  Jyske Bank  A/S (CSE:JYSK) was up 0.18% or 1.00 points to 554.50 in late trade. The worst performers of the session were Tryg A/S (CSE:TRYG), which fell 4.20% or 6.70 points to trade at 153.00 at the close. Coloplast A/S (CSE:COLOb) declined 2.64% or 19.20 points to end at 707.20 and  Novo Nordisk  A/S Class B (CSE:NOVOb) was down 2.59% or 12.40 points to 466.60. Falling stocks outnumbered advancing ones on the Copenhagen Stock Exchange by 97 to 39 and 14 ended unchanged. Shares in Coloplast A/S (CSE:COLOb) fell to 52-week lows; down 2.64% or 19.20 to 707.20. Shares in Novo Nordisk A/S Class B (CSE:NOVOb) fell to 52-week lows; down 2.59% or 12.40 to 466.60.  Crude oil for May delivery was up 0.34% or 0.24 to $71.44 a barrel. Elsewhere in commodities trading, Brent oil for delivery in June rose 0.16% or 0.12 to hit $74.61 a barrel, while the June Gold Futures contract rose 0.64% or 20.19 to trade at $3,166.19 a troy ounce. USD/DKK was down 0.58% to 6.87, while EUR/DKK unchanged 0.01% to 7.46. The US Dollar Index Futures was down 0.42% at 103.51. With NOVOb making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed NOVOb alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including NOVOb, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is NOVOb poised for similar growth? Don't miss the opportunity to find out. 